A MULTI-STAKEHOLDER (PHYSICIAN, PAYER, PATIENT, AND INDUSTRY) QUALITATIVE ANALYSIS OF THE POLICIES THAT WOULD SUPPORT A SUSTAINABLE EUROPEAN BIOSIMILARS MEDICINES MARKET COMBINED WITH A QUANTITATIVE ANALYSIS OF THE MULTI-STAKEHOLDER BENEFIT ...
Author(s)
Whitehouse JT1, Teale CW1, Glover JC1, Taylor C1, Lino Mendonca V2
1GfK Market Access, Melton Mowbray, UK, 2European Generic Medicines Association (EGA), Brussels, Belgium
OBJECTIVES: To establish the key policy areas that will drive the establishment of a sustainable biosimilar medicines market. To outline the benefits that these will bring to Physicians, Payers, Patients, and Industry, with particular focus on the benefits for European National Health systems. METHODS:
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PHP28
Topic
Health Policy & Regulatory
Topic Subcategory
Pricing Policy & Schemes
Disease
Multiple Diseases